Characteristics of treated advanced lung cancer (n=85)
| Age year | 67 (48–84) |
| Sex male | 60 (70.6%) |
| Race | |
| Chinese | 77 (90.5%) |
| Malay | 6 (7.0%) |
| Indian | 2 (2.3%) |
| Advanced lung cancer with CAO requiring re-canalisation | 43 (50.6%) |
| Advanced lung cancer without CAO | 42 (49.4%) |
| Presenting symptom | |
| Cough | 42 (49.4%) |
| Dyspnoea | 39 (45.8%) |
| Respiratory failure | 15 (17.6%) |
| Intubation for respiratory failure | 10 (11.7%) |
| Haemoptysis | 19 (22.3%) |
| Hoarseness | 3 (3.5%) |
| Histology | |
| Adenocarcinoma | 30 (35.2%) |
| Squamous cell carcinoma | 19 (22.3%) |
| Non-small cell lung cancer | 17 (20%) |
| Small cell carcinoma | 10 (11.7%) |
| Sarcomatoid carcinoma | 3 (3.5%) |
| Others | 5 (5.8%) |
| Stage | |
| Stage IIIA | 14 (16.4%) |
| Stage IIIB | 13 (15.2%) |
| Stage IV | 58 (68.2%) |
| Recanalisation | 43 (50.6%) |
| Laser resection | 25 (29.4%) |
| Stent placement | 17 (20%) |
| Both | 3 (3.5%) |
| Cancer specific therapy | |
| Epidermal growth factor receptor mutation Exon 19 and 21 | 8 (9.4%) |
| Chemotherapy | 34 (40%) |
| Radiotherapy | 41 (48.2%) |
| TKI | 13 (15.2%) |
| Survival | |
| Deaths | 72 (84.7%) |
| Survival months | 9.4 (0.8–79.4) |
| <3 months | 22 (25.8%) |
| ≥3 months | 63 (74.1%) |
| ≥6 months | 55 (64.7%) |
| ≥12 months | 31 (36.4%) |
| >24 months | 8 (9.4%) |
| ≥5 years | 4 (4.7%) |
Data are presented as median (range) unless otherwise stated. CAO: central airway obstruction; TKI: tyrosine kinase inhibitors.